MassBio Annual Meeting
Monday, March 26 – Tuesday, March 27 2012
- Francis S. Collins, Director, National Institutes of Health
- Eric D. Perakslis Ph.D., Chief Information Officer & Chief Scientist (Informatics), U.S. Food and Drug Administration
- Edward Scolnick, Core Member & Director of the Psychiatric Disease Program, Broad Institute of MIT and Harvard; Professor of the Practice in the Department of Biology, MIT
- Gunjan Aggarwal, Global Head, TM&OD and Staffing, Novartis Vaccines & Diagnostics
- Nurjana Bachman, Business Development Manager, Children's Hospital Boston
- William Bachovchin, Ph.D., Executive Vice President and Chief Scientific Officer, Co-Founder, Arisaph Pharmaceuticals, Inc.
- John Beeler, Director, Theranostics and Business Development, bioMerieux
- Kees Been, CEO, EnVivo
- Diana W. Bianchi, Vice Chair for Research, Floating Hospital for Children
- Kevin J. Bitterman, Principal, Polaris Venture Partners
- Joshua Boger, Founder, former CEO and current board member, Vertex Pharmaceuticals – 2012 recipient of Henri A. Termeer Innovative Leadership Award
- Bruce Booth, Partner, Life Sciences Group, Atlas Venture
- Jeffrey Borenstein, Director, Biomedical Engineering Center, Draper Labs
- Barrett Bready, CEO, Nabsys
- John Butler, CEO, Inspiration Biopharmaceuticals
- Jeremy Caldwell, Vice President, RNA Therapeutics, Screening and Protein Sciences, Merck
- Abbie Celniker, CEO, Eleven Biotherapeutics
- Pravin Chaturvedi, Chief Executive Officer (CEO), IndUS Pharmaceuticals
- Michael Cicio, VP Operations and Site Manager, New England Operations, Lonza Biologics
- Jerry Conway, Vice President of Payor Contracting & Reimbursement, Metamark Genetics, Inc.
- Silvia Corvera, Professor, Program in Molecular Medicine, University of Massachusetts Medical School
- Daniel J. Curran, Vice President, Business and Corporate Development, Millennium: The Takeda Oncology Company
- Bryan Dechairo, Senior Director, Development Head, Medco
- Horst Domdey, Managing Director, BioM-Munich Biotech Cluster
- Erling Donnelly, Director, Worldwide Regulatory Strategy, Pfizer Inc.
- Jeff Elton, Jeffrey Elton, Managing Director, Accenture; former Global COO & Strategy Head, Novartis Institutes for BioMedical Research
- Juan Enriquez, Managing Director, Excel Venture Management
- Douglas Fambrough, CEO & co-founder, Dicerna Pharmaceuticals
- Martha C. Farmer, President and CEO, North Shore InnoVentures
- Brian Fenton, Senior Director Business Development, Shire HGT
- Jessica Baker Flechtner, Vice President of Research, Genocea Biosciences, Inc.
- Richard M. Freeland, Commissioner, Massachusetts Dept. of Higher Education
- Brian M. Gallagher, Jr., Partner, SR One Ltd.
- Karen Gallant, Vice President SPBD Infection, AstraZeneca
- Tillman Gerngross, Founder & CEO, Adimab
- Steven C. Gilman, Executive Vice President, Research & Development and Chief Scientific Officer, Cubist Pharmaceuticals
- Alexandra Glucksmann, Senior Vice President, Research and Business Operations, Cerulean Pharma
- Eric B. Gordon, CEO and President, Atentiv Inc.
- Gary L. Gottlieb, President and Chief Executive Officer, Partners HealthCare System, Inc.
- John Harrington, Chief Commercial Officer, Sanofi-Aventis Oncology
- Sheela Hegde, Vice President, Health Advances
- John K. Hennessy, Executive Director & General Manager, AstraZeneca R&D Boston
- Michael W. Henry, Vice President, Business Development, Athena Diagnostics Inc.
- John Hession, Partner, Venture Capital Financings and Emerging Companies, Cooley, LLP
- Gigi Hirsch, Executive Director, MIT Center for Biomedical Innovation
- Donna Hochberg, Manager, Health Advances
- Kevin Hrusovsky, Senior Vice President and President, Life Sciences and Technology, PerkinElmer
- Mike Jirousek, Co-founder and Chief Scientific Officer, Catabasis
- Ed Kania, Managing Partner and Chairman, Flagship Ventures
- Mickey Koplove
- Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
- Ralph Lambalot, DVP Biologics Development & Manufacturing Launch, Abbott Laboratories
- Tomas Landh, Director, Strategy and Sourcing, Diabetes Research Unit, Novo Nordisk
- Scott Lauder, Senior Director and Global Head, Protein and Cell Sciences, EMD Serono
- Carl W. Lawton, Director, Massachusetts Biomanufacturing Center, UMass Lowell
- Daniel Levy, M.D., Director, Framingham Heart Study, & Director, Center for Population Studies, National Heart, Lung and Blood Institute (NHLBI)
- Jeffrey P. Libson, Partner, Pepper Hamilton LLP
- Phil Litos, Chief Operating Officer, Bostonian Group
- John Maraganore, CEO, Alnylam Pharmaceuticals
- Barbara Hedgis McGovern, Associate Professor, Tufts University School of Medicine, Division of Infectious Diseases, Lemuel Shattuck Hospital
- Donnie McGrath, Global Head, Virology and Neuroscience Strategic Transactions, Bristol-Myers Squibb
- Philip McGurk, Senior Director, Pfizer, Inc.
- Michael A. Metzger, Executive Vice President and Chief Operating Officer, Mersana Therapeutics
- Vincent Miles, Venture Partner, Abingworth
- Glenn Miller, VP & Head of Personalized Healthcare, AstraZeneca
- Emily Minkow, Assoc. Director of BD, Celgene Corporation
- Jay Mohr, Managing Director, Locust Walk Partners
- Craig Muir, Partner, Third Rock Ventures
- Imran Nasrullah, Head of Strategic Alliances, T1D First
- Sridaran Natesan, Ph.D., Scientific Site Head (R&D), Sanofi (Cambridge,MA)
- Garry Neil, Corporate Vice President, Corporate Office of Science and Technology (COSAT), Johnson & Johnson
- Susan Nemetz, President, The NemetzGroup
- Vinit Nijhawan, Managing Director, Technology Development Office, Boston University
- Yat Sun Or, Ph.D., Sr. VP, Research & Development and Chief Scientific Officer, Enanta
- Scott D. Patterson, PhD, Executive Director, Medical Sciences, Amgen Inc.
- Michael Pellini, CEO, Foundation Medicine
- Manos Perros, Head of Infection, AstraZeneca
- Deanna M. Petersen, Vice President Business Development, Shire HGT
- John J. Reddington, Chief Operating Officer, Cambridge Biomedical
- David Resnick, Co-Leader, Patents Practice, Nixon Peabody
- Tim Rowe, CEO, Cambridge Innovation Center
- Alfred W. Sandrock, MD, PhD, Senior Vice President, Medical Research Neurology, Biogen Idec
- Thomas Scholl, Vice President, Research & Development, Integrated Genetics/LabCorp
- David Schenkein, CEO, Agios Pharmaceuticals
- Dennis J. Selkoe, Co-Director, Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital
- Juswinder Singh, CSO, Avila Therapeutics, Inc.
- John Z. Sullivan-Bólyai, Vice President, Clinical Research, Idenix Pharmaceuticals
- Barbara Tate, Vice President of Biology, Satori Pharmaceuticals
- Henri A. Termeer, former Chairman, President and CEO, Genzyme Corporation– Presenter, Henri A. Termeer Innovative Leadership Award
- Steven Tregay, Founder, President and CEO, FORMA Therapeutics
- Akshay Vaishnaw, Senior Vice President and Chief Medical Officer, Alnylam Pharmaceuticals
- Ajay Verma, Vice President, Translational Neurology, Biogen Idec
- Jeff Voss, Senior Principal Research Scientist, Abbott Bioresearch Center and member of FNIH steering committee for Inflammation and Immunology
- Charles Wilson, Vice President and Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research (NIBR)
- Tod Woolf, Chief Business Officer, X-BODY Biosciences
- Paul Young, Chief Scientific Officer, Syndexa Pharmaceuticals
- Tal Zaks, Vice President, Oncology Clinical Development, Sanofi
- Daphne Zohar, Founder & Managing Partner, PureTech Ventures
Eric is currently Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration. In this new role, Eric is responsible for modernizing and enhancing the IT capabilities as well as the in silico scientific capabilities at FDA.
Prior to FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and was a member of the Corporate Office of Science and Technology. During his thirteen years at J&J, Eric also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology as well as assistant Director and Director of Drug Discovery Research prior to his current role. Before joining J&J, Eric was the Group leader of Scientific Computing at ArQule Inc. and he began his professional career with the Army Corps of Engineers.
Eric has a PhD in chemical and biochemical engineering from Drexel University and also holds B.S.Che and M.S. degrees in chemical engineering. Eric’s current research interests are enterprise knowledge management, patient stratification, healthcare IT and translational informatics with the specific focus precompetitive data sharing, and open source systems globalization.
Eric is a late-stage kidney cancer survivor and an avid patient advocate. He has served as the Chairman of the Survivor Advisory Board at the Cancer Institute of New Jersey and as the Chief Information Officer of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan. Eric has also worked extensively with the Lance Armstrong Foundation, the Kidney Cancer Association, the Scientist ó Survivor program of the American Association for Cancer Research, OneMind4Research and several other top non-profit disease-based organizations to further their domestic and international agendas.
Eric’s personal interests include sailboat racing, back-country snowboarding, rock climbing, cycling, running marathons and operating his family vineyard and winery. Eric lives in Doylestown, Bucks County Pennsylvania with his wife Lisa Gail and 10-year old daughter Sammy.
An accomplished HR business partner with over 14 years of experience in senior HR roles across US, UK, Switzerland and India, Gunjan has worked closely with the executive leadership teams of Unilever and Novartis Pharmaceuticals to drive the corporate HR agenda across global/regional organizations.
A trusted advisor and coach to executives, Gunjan specializes in aligning the HR strategy of organizations for corporate success in areas of organization-wide change management, restructuring in situations of business acquisition and divestiture, development of a strategic compensation and rewards strategy geared towards growth, executive leadership development and coaching, succession planning, and in development of a winning organization culture.
As an HR leader, Gunjan brings cross-functional and global experience from Fortune 50 corporations – including two that Fortune ranks among the World’s Most Admired Companies and top 25 companies for leadership (2011).
A thought leader in HR, Gunjan has been a key note speaker and has written articles for various publications like ASTD, New England Journal of Technology and OD Practitioner. She is a board member of SHRM Global Human Metrics Expertise panel, executive board member of Novartis Learning board, Novartis global D&I council, and a member of the CLO Network advisory board.
Gunjan is currently the Global Head for Talent Management, Organization Development and Staffing at Novartis Vaccines & Diagnostics. Most recently, she was Senior Director HR for Global Technical Operations in Vaccines & Diagnostics, and prior to that, she was the Head of Learning & Development for Novartis Institutes for Biomedical Research (NIBR).
Before joining Novartis, she worked in various roles of increasing responsibility in Unilever, the key roles being Unit HR Head of a Foods plant, Regional Site HR Head of Unilever Research Facility, and Global Organization Effectiveness Leader for Corporate HR based out of India and UK, respectively.
Gunjan completed her undergraduate degree in Engineering in Electronics and Communications with highest honors and her graduate degree in Master of Business Administration (MBA) as a valedictorian from Xavier’s Labour Relations Institute (XLRI), India.
Dr. Bachovchin serves as Executive Vice President and Chief Scientific Officer, and has been a Director since he co-founded the Company in 1999. Dr. Bachovchin is a leader in the areas of boronic acid chemistry and enzyme biochemistry. Dr. Bachovchin's work has led to the discovery of several candidate drugs and to the formation of Point Therapeutics, Inc., which was a publicly traded biotechnology company prior to its merger with DARA BioSciences, Inc. Dr. Bachovchin has published more than 80 peer reviewed journal articles and has been an invited speaker to numerous scientific conferences. Dr. Bachovchin is an inventor on 12 issued patents and on numerous pending patent applications covering a variety of novel drug compounds and methods of treatment.
In addition to his role at Arisaph, Dr. Bachovchin is a Professor of Biochemistry at Tufts University School of Medicine, where he has served as a faculty member for nearly 30 years. Dr. Bachovchin completed his postdoctoral work with J.D. Roberts at the California Institute of Technology and at Harvard Medical School. Prior to his postdoctoral work, Dr. Bachovchin received his Ph.D. in chemistry from the California Institute of Technology and his B.S. from Wake Forest University.
Kees Been has served as president and chief executive officer since 2005 and brings more than 15 years of experience to EnVivo. Prior to joining EnVivo, Kees was chief executive officer of Bionaut Pharmaceuticals, a biotechnology company using a proprietary cell-based discovery platform to advance drug candidates for cancer and inflammation. Prior to his work at Bionaut, Kees spent four years at Biogen where he directed the Oncology Business Unit and, as senior vice president of business development, led all of Biogen’s deal-making efforts and portfolio management activities. Major deals he oversaw include the collaborations with Elan on Antegren® (now Tysabri®), with ICOS on the oral LFA-1 antagonist, and with EOS Biotechnology on breast cancer target discovery. Before his work with Biogen, Kees held executive positions with Monsanto Life Sciences Company, involving corporate modification projects and large growth strategies in Latin America. Prior to that, Kees worked at Gemini Consulting where he last served as vice president and was responsible for building the pharmaceuticals practice. He began his career as a scientist on the Interferon-gamma project at Biogen in Geneva, Switzerland. He earned an M.B.A. degree from INSEAD in France and a B.S. degree in Molecular Biology and Process Engineering from the University of Agriculture in Holland.
Dr. Celniker brings more than 20 years of proven expertise in building late-stage protein therapeutic discovery and development programs and biologics-focused businesses to Eleven Biotherapeutics. Prior to leading Taligen, Dr. Celniker was global head of biologics at Novartis, where she oversaw the biologics division, forged strategic alliances and led internal discovery and development to build the pipeline. Prior to Novartis, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeutics and pharmaceutical sciences. Previously, she held senior research and development leadership roles with Wyeth BioPharma (Genetics Institute) and Genentech. Dr. Celniker holds a Ph.D. in molecular biology from the University of Arizona and a B.A. in biology from the University of California, San Diego.
Dr. Chaturvedi currently maintains a dual role of being the Chief Executive Officer (CEO) of IndUS Pharmaceuticals and the Chief Scientific Officer (CSO) of Napo Pharmaceuticals. Dr. Chaturvedi founded of Boston-based IndUS Pharmaceuticals in 2005 and IndUS was acquired by San Francisco-headquartered Napo Pharmaceuticals in 2007 and in 2010, Dr. Chaturvedi successfully spun IndUS out. Prior to IndUS, he was a co-founder and President & CEO of Scion Pharmaceuticals, which focused on the discovery and development of a novel, first-in-class drug, for the treatment of moderate-to-severe and neuropathic pain, which was sold to Wyeth. Prior to Scion, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals as the Senior Director and Head of Lead Evaluation and before that he was in the preclinical group at Alkermes. Prior to Alkermes, he was in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer), where he worked on the development of new drugs for the treatment of oncology, epilepsy, pain and cognition. He has participated in the discovery and/or development of six marketed drugs for the treatment of CNS disorders, HIV and hepatitis C. He has authored or co-authored approximately 50 publications and he is an inventor or a co-inventor on several patents and patent applications. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay. Dr. Chaturvedi is or has served on the Boards of Scion Pharmaceuticals, IndUS Pharmaceuticals, Sindu Pharmaceuticals and Sindu Research Laboratories, as well as TiE Boston.
Jerry Conway joins Metamark Genetics with over 20 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces working first in physician sales and marketing, then later with national and regional payors on contracting, education and utilization management initiatives involving laboratory services. His experience includes payor contracting and reimbursement in a wide range of business environments including Fortune 500 and start-up companies. In 1997, Jerry joined Genzyme Genetics, a national provider of genetic health services, to develop business relationships and contracts with regional and national payors based in the Northeastern United States. In 2001, he was promoted to the role of Director of National Accounts with Genzyme Genetics and was responsible for business development and contracts with national and cross-regional payors. In 2004, Jerry was promoted to Vice President of Managed Care where he oversaw a staff of 11 regional and national account directors who were focused on payor account management, contracting, pull through, education and care management programming. With a particular focus on reimbursement for routine and novel genetic tests and services in the reproductive and oncology markets at Genzyme Genetics, Jerry has a demonstrated track record of increased revenue and profitability. Under his leadership in payor contracting and reimbursement over 14 years, Jerry helped to favorably position the company for a recent $975 million acquisition by Laboratory Corporation of America® Holdings on December 1, 2010.
Daniel Curran joined Millennium Pharmaceuticals in 1999 as a Director of Business Development. From 1999 to 2003, he played a key role in Millennium’s business development activities and was a driving force for strategic business transactions in the inflammation and cardiovascular disease franchises. In 2003, he moved to Millennium’s research and development organization and assumed leadership for two inflammation development programs: MLN1202 and MLN0415. In this role, Dan led the programs through Phase 1 and Phase 2 trials in a number of auto-immune disease indications.
Dan rejoined the corporate development group in 2006 as vice president and is responsible for strategic business transactions for Millennium. He has served as the primary negotiator of numerous transactions with major pharmaceutical and biotechnology companies during his ten year tenure at Millennium, including the recent acquisition of Millennium by Takeda Pharmaceuticals.
Prior to Millennium, Dan’s previous professional experiences include a business development role in the Product Planning and Acquisition group at DuPont Merck Pharmaceuticals. He completed his residency in Internal Medicine and served as Chief Medical Resident at Beth Israel Deaconess Medical Center in Boston. Dan holds an M.D. from the University of Pennsylvania, an M.B.A. from The Wharton School of Business, and a B.S. in Chemistry from King’s College. A native of Pennsylvania, Dan currently resides in Wellesley, Massachusetts.
Juan Enriquez is a leading authority on the economic impact of life sciences on business and society and is a respected business leader and entrepreneur. Juan represents Excel on the boards of Shape Up, Activate Networks, Fina Technologies, Catch.com, and Synthetic Genomics. He also serves on the Boards of WGBH, Museum of Science, David Rockefeller Center for Latin American Studies, PersonalGenome.org and Tufts Institute for Global Leadership.
Prior to Excel, Juan was the founding Director of the Harvard Business School's Life Sciences Project, with many of his innovative thoughts captured in his bestselling book, As The Future Catches You, which provided an accurate blueprint of how a bio-based economy changes industries and corporations.
His most recent publication written with co-author Steve Gullans, is an eBook, Homo Evolutis: A Short Tour of our New Species, which describes a world where humans increasingly shape their environment, themselves, and other species.
Following HBS, Juan became an active angel investor and founder of Biotechonomy Ventures which invested in BioTrove, Xcellerex, and Synthetic Genomics, a company he co founded with Drs. J. Craig Venter and Hamilton Smith to apply life sciences to diverse markets. As a business leader, advisor, and renowned speaker, Juan works directly with the CEOs of a number of Fortune Fifty companies, as well as various heads of state, on how to adapt to a world where the dominant language is shifting from the digital towards the language of life. He is a member of the Board of Directors of Cabot Corporation (NYSE: CBT) and he graduated from Harvard with a B.A. and an M.B.A., both with honors.
Douglas Fambrough is a co-founder of Dicerna Pharmaceuticals and joined the company as CEO in May 2010. Prior to joining Dicerna, Dr. Fambrough spent over a decade as a biotechnology venture capitalist with Oxford Bioscience Partners, one of Dicerna’s investors. At Oxford, he specialized in financing innovative life science technology companies such as the first generation RNA interference company, Sirna Therapeutics. Among his other investments are high-throughput DNA sequencing pioneer Solexa (acquired by Illumina); Xencor, which engineers antibody Fc domains to enhance drug properties; Rib-X Pharmaceuticals, a developer of antibiotics against multi-drug resistant pathogens; and Solstice Neurosciences, which markets the protein drug Myobloc for movement disorders. Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).
Dr. Fambrough graduated from Cornell University and holds a Ph.D. in genetics from the University of California, Berkeley.
Martha C. Farmer, PhD is President and CEO, North Shore InnoVentures, a non-profit business incubator designed to accelerate the growth of life sciences and cleantech start-ups. Prior to serving with NSIV, Martha was a Fellow in Medical Ethics at Harvard Medical School which led to a consulting role with the Harvard Embryonic Stem Cell Research Oversight Committee and with a stem-cell start-up, StemCore. Formerly with Baxter Healthcare’s Hemoglobin Therapeutics Division for eleven years, Martha transitioned from managing the research laboratory to directing product development, marketing and communications. She subsequently consulted for several firms in clinical development of blood substitutes as well as for the DoD and NIH. She also co-founded the radiopharmaceutical start-up, BetaGamma LLC, serving as Vice President of Marketing. Martha serves on the Board of Trustees of the North Shore Community College and on the Board of Directors of the North Shore Technology Council where she chairs the Council’s Biomedical Technology Section.She also serves on the Institutional Review Board and Ethics Committee of Northeast Hospital Systems and the Ethics Committee of Hospice of the North Shore.Martha earned a BS in zoology and PhD in physiology and pharmacology from Duke University, postdoctoral training in biophysics from Johns Hopkins University, and is an author on more than 30 publications and three patents.
Brian established the SR One Boston office in 2010 and is focused on building innovative therapeutic and device life science companies. He currently represents SR One on the boards of Aileron Therapeutics, Constellation Pharmaceuticals, Dicerna Pharmaceuticals, RaNA Therapeutics, and SpringLeaf Therapeutics. He has nearly 15 years of investing, business development, operational, and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals where he was responsible for corporate development, operations, and post-merger integration following the $720 million acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Brian was with Alantos Pharmaceuticals where he played key roles in the R&D and business development activities, and led many aspects of the post-merger integration following the $300 million acquisition of Alantos by Amgen in 2007. Brian began his career in R&D at the Japanese pharma Eisai where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas. He is an inventor on over twenty-five patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the editorial board of the journal Marine Drugs and is a peer reviewer for numerous journals and research funding authorities. Brian received his M.S. and Ph.D. degrees in Organic Chemistry from The University of Michigan, and a B.S. in Chemistry from The University of Massachusetts where he was awarded a full scholarship.
Steven C. Gilman, Ph.D. has served as our Executive Vice President, Research & Development and Chief Scientific Officer since September 2010. From February 2008 until September 2010, Dr. Gilman served as Senior Vice President, Discovery & Non-Clinical Development and Chief Scientific Officer. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves on the board of directors of the Massachusetts Biotechnology Association and Inhibikase, Inc., a privately held biotechnology company. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.
John Harrington is the Chief Commercial Officer for Sanofi-Aventis Oncology. In this role, John is responsible for the Global Marketing and Sales responsibilities for the Sanofi-Aventis Oncology Portfolio. He reports directly to Debasish Roychowdhury, the Senior Vice President and Head of the Oncology Team.
John has had 35 years experience in the pharmaceutical industry. Most recently, he has led the Sanofi-Aventis US Oncology Business Unit and prior to that the Sanofi-Aventis Diabetes Business Unit. He has had extensive general management experience including being the Vice President of Sales for Aventis Pharmaceuticals, Primary Care Sales, Vice President and General Manager of the West Region for Hoecsht Marion Roussel and also establishing one of the industry’s first managed care teams for Marion Laboratories, Marion Merrell Dow and Hoecsht Marion Roussel, Inc.
John is currently a member of ASCO and ASCR. He has previously been an active member of the Diabetes Association and the ADA’s Industry Advisory Council.
Up until his relocation to Massachusetts, John was a Board Member of the Somerset Medical Center and also the Drug Distribution Research Center. From a community respective, he is a member of the Ancient Order of Hibernians and the Sons of Erin of Cape Cod. John is married to his wife Susan and has three children. He holds a Bachelors of Arts from Stonehill College and earned his MBA at Rockhurst University in Kansas City.
Sheela joined Health Advances in 2005 with a strong background in corporate strategy and health care provider operations. Prior to Health Advances, Sheela worked at The Advisory Board where she managed client relationships and led research teams in areas related to hospital operational improvement issues and health plan strategic issues. She also worked at Novartis Pharmaceuticals in the Cardiovascular Business Franchise, helping formulate franchise growth strategies for the Japan business.
At Health Advances, Sheela has worked with a wide variety of medical device, pharmaceutical, and biotech clients ranging from small start-ups to some of the largest public companies in the industry. She has particular expertise in cardiovascular, renal, and diabetes products, as well as general expertise in new product commercialization, product lifecycle planning, and M&A strategy.
Sheela earned a BA in human biology with university distinction and Phi Beta Kappa from Stanford University, and an MBA from the Harvard Business School.
As Executive Director and General Manager at AstraZeneca R&D Boston, Mr. Hennessy chairs the R&D Boston Site Leadership Team and is responsible for ensuring the delivery of quality services ranging from human resources to facilities and engineering that enable scientists on-site to focus on developing innovative therapies for cancer and infectious disease using powerful new technologies. He was responsible for overseeing the $100,000,000 expansion completed in Spring 2009, which brought the total size of the research facility to 382,000 square feet.
He has served on the MassBio Board of Directors since 2004, where he also serves as the Board representative to the Purchasing Advisory Group and on the executive committee of the Mass Life Sciences Education Consortium, a program of the MassBioEd Foundation. In Waltham, MA, where AstraZeneca R&D Boston is located, Mr. Hennessy is an active member of the Board of the Waltham/West Suburban Chamber of Commerce. He is a past president of the Waltham Partnership for Youth, and continues to serve on that Board of Directors.
Mr. Hennessy began his career in 1981 as an audit manager with Grant Thornton, CPAs. After holding the position of Corporate Controller at Groundwater Technology Inc., he then served as Director of Finance for GTEL Environmental Labs, Inc. Mr. Hennessy joined AstraZeneca in 1996 as Site Finance Director.
Mr. Hennessy is a member of the American Institute of CPAs, Financial Executives International and the Massachusetts Society of CPAs, and is a certified public accountant in the Commonwealth of Massachusetts. He holds a Bachelor's degree in Accounting from the University of Indiana.
Michael W. Henry is Vice President, Business Development, at Athena Diagnostics Inc., a part of Quest Diagnostics. He has over 20 years of experience in biotechnology business development. At Athena, he collaborates with gene hunters who discover new disease genes, launches new genetic tests, and serves on the senior leadership team that sold Athena to Fisher Scientific for $283 million in 2006, and to Quest for $740 million in 2011.Previously, Mr. Henry served as Vice President, Business Development, at Avant Immunotherapeutics Inc., now merged with Celldex. Prior to Avant, he worked in academic medical centers, serving as Senior Director, Licensing and Ventures, at University of Massachusetts Medical School, and Director, Technology Transfer, at Children’s Hospital of Philadelphia. Prior to CHOP, he served as Manager, New Business Development, at Allelix Inc., Mississauga, Ontario. Recognized as a National Science Foundation Graduate Fellow as a PhD student at University of California Berkeley, Mr. Henry received an MBA and an MS from University of California Berkeley, and a BS from University of Michigan.
Mike Jirousek, Catabasis co-founder and chief scientific officer, has more than 20 years of experience in pharmaceutical research and development. Prior to joining Catabasis, he was a corporate officer and senior vice president of research at Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), where he was head of research for the company. Dr. Jirousek's team produced several first-in-class SIRT1 modulators that are in Phase 1 and 2 studies, with additional compounds in IND-enabling toxicology studies. He joined Sirtris from Pfizer La Jolla, part of Pfizer Global Research and Development, where he was senior director and head of the metabolic therapeutic area. Dr. Jirousek founded the La Jolla group, growing the effort over the course of five years into a highly productive team that produced six clinical candidates.
Prior to joining Pfizer, Dr. Jirousek was the department head at Abbott Laboratories for three years. In this role, he focused on discovering and developing new agents to overcome leptin and insulin resistance, of which several clinical candidates resulted from his groups' programs. Dr. Jirousek spent eight productive years at Eli Lilly in Indianapolis and Hamburg, Germany, focusing on diabetic complications and PKC inhibitors. He also worked in the field of small molecule approaches to improve islet function and mimics of GLP-1 action.
Throughout his career in drug discovery and development, Dr. Jirousek has been responsible for co-inventing and/or bringing 12 compounds from inception into clinical trials as potential new therapeutics to treat cancer, obesity, diabetes and diabetic complications. He has co-authored more than 170 peer-reviewed papers, abstracts and patents.
Dr. Jirousek holds a Ph.D. in chemistry from Case Western Reserve University and was a postdoctoral fellow at Harvard University.
Ed Kania is Managing Partner and Chairman of Flagship Ventures, a firm he co-founded in 2000. Ed has 27 years of experience in the venture capital industry. Prior to co-founding Flagship Ventures in 2000, he spent 14 years as General Partner of OneLiberty Ventures and of its predecessor firm, Morgan, Holland Ventures. From 1983-1984 he served as an Investment Officer at First Capital Corporation of Boston, the venture capital subsidiary of Bank of Boston, and, previously, as Research Associate at Harvard Business School and as General Manager at J. Cunningham, Inc. He is a frequent speaker on venture capital and entrepreneurship. Ed earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard Business School. While at Dartmouth, he was an All-American Track and Field athlete and a national and collegiate record holder.
Throughout his professional career, Ed has operated both as an investor and as an active partner to entrepreneurs in company building. His direct investment experience covers over 100 companies. In addition, he has been intimately involved in the launch and development of more than a dozen companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. Several of these companies are now publicly traded while others have been acquired by significant publicly-traded companies. The total value of the companies in which Ed has participated as founding or lead investor is currently several billion dollars. Among the companies for which Ed has served as an active Director are Adolor (NASDAQ: ADLR), Alere Corp. (purchased by Inverness Medical), Anesta Corp. (NASDAQ: NSTA, purchased by Cephalon), Aspect Medical (NASDAQ: ASPM, purchased by Covidien), AudioLogic (purchased by Cirrus Logic), ChemGenics Pharmaceuticals (purchased by Millennium), Cytyc Corp. (NASDAQ: CYTC), EXACT Sciences (NASDAQ: EXAS), Interactive Supercomputing (acquired by Microsoft), Ontogeny (merged into Curis, NASDAQ: CRIS), PerSeptive Biosystems (NASDAQ: PBIO, purchased by Applera), Somatogen (NASDAQ: SMTG, purchased by Baxter), and VisEn Medical (acquired by PerkinElmer). He was also a founding investor in IDEXX Laboratories (NASDAQ: IDXX) and in TripAdvisor (purchased by InterActive Corp).
Currently, Ed is a Director of Flagship portfolio companies Acceleron Pharma, ExactCost, INTIO, Pervasis Therapeutics, TARIS Biomedical, TransMedics, and Visterra.
Ed also serves as Co-Chairman of the Board of Directors of Common Impact, a non-profit organization that connects skilled professionals from global corporations to local, high potential non-profits. He is a director of MassBio, a not-for-profit organization that works in support of the Massachusetts biotechnology industry, and a member of The Johns Hopkins Medicine Alliance for Science and Technology Development Industry.
Raju Kucherlapati came to the United States in 1967 after receiving his B.S. in Biology at P.R. College, Kakinada, India and his M.S. in Biology at Andhra University, Waltair, India. He received his Ph.D. from the University of Illinois at Urbana and did his post-doctoral work in the lab of Frank Ruddle at Yale University. He was assistant professor in the Department of Biochemical Sciences at Princeton University, then became professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department of Molecular Genetics, a position he held for eleven years. In 2001 Dr. Kucherlapati became the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). At HPCGG Dr. Kucherlapati devoted his energies to advancing the cause of personalized medicine. Under his direction HPCGG launched initiatives that resulted in a large number of novel molecular diagnostics; built new information technology programs that captured the results of clinical and basic genetic research in structured formats that could then be applied meaningfully in clinical decision making that would benefit diagnosis, prognosis and treatment of patients. He also strengthened and developed new training and educational programs for physicians, scientists, healthcare professionals, patients, and others in human genetics and genomics and the application of genetics in healthcare. He stepped down as the Scientific Director of the Center in late 2008. He continues to promote personalized medicine in all of its facets at the national level. Dr. Kucherlapati contributed to several different areas of research. These include gene targeting and homologous recombination, human gene mapping, generation of physical maps of the human genome with special emphasis on human chromosome 12, development of techniques to modify genes in mammalian cells and in cloning many human disease genes. To date he holds 12 patents. He was a member and Chair of several review committees at the NIH, was a member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and was a co-chair of the steering committee for the National Cancer Institute’s Mouse Models for Human Cancer Consortium. He served on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics. He is a fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Kucherlapati was a founder of Cell Genesys, Abgenix and Millennium Pharmaceuticals. He currently serves on the boards of privately held AVEO Pharmaceuticals and Enlight Biosciences.
Daniel Levy, MD, joined the Framingham Heart Study in 1984 after completing his cardiology fellowship at Harvard's Brigham and Women's Hospital and Harvard School of Public Health.
Dr. Levy is a Medical Officer of the National Heart, Lung, and Blood Institute and has a faculty appointment at Boston University School of Medicine, where he is Professor of Medicine. Dr. Levy has published over 200 articles in leading medical journals, and edited a book on the Framingham Heart Study titled 50 Years of Discovery. He serves on the editorial boards of the Journal of Hypertension and the American Journal of Medicine.
He became the Framingham Heart Study's fourth director in 1994. Dr. Levy is a fellow of the American College of Cardiology and an active member of the American Heart Association's Council on Hypertension and the American Society of Hypertension.
In addition to his research and administrative responsibilities, Dr. Levy has become actively involved as a policy maker. He served with the National High Blood Pressure Education Program and the National Cholesterol Education Program in the formulation of national hypertension and cholesterol guidelines.
Dr. Levy has been the recipient of many awards including the National Institutes of Health Director's Award given for his research achievements at the Framingham Heart Study. His main areas of research interest include the epidemiology and genetics of hypertension, heart disease and heart failure.
Jeffrey P. Libson is a Corporate and Securities partner in the Berwyn office of Pepper Hamilton LLP. He is the head of the firm’s life sciences practice. Mr. Libson’s practice is devoted primarily to the areas of securities law, venture financing, mergers and acquisitions, corporate governance and the commercialization, licensing and acquisition of intellectual property.
He represents a number of publicly traded and closely held life science companies in ongoing representations as outside general counsel. He also represents a number of nonprofit entities that support the life sciences industry.
Within the securities and venture financing practice areas, Mr. Libson has represented investment banks and issuers in public offerings (including initial public offerings) and private placements of equity and debt securities, and has represented both funding sources and companies in venture financing transactions.
Within the mergers and acquisitions practice area, Mr. Libson has represented buyers, sellers and investors in numerous acquisition, disposition and combination transactions, affecting both public and private companies. Company industries include biotech, diagnostics, pharmaceutical, health care and e-health, and communications, among others.
Within the intellectual property practice area, Mr. Libson has represented numerous companies, including pharmaceutical companies, biotechnology companies, consumer products companies, computer software developers and R&D contractors, in corporate partnering transactions, the acquisition and licensing of patents, trademarks, copyrights and trade secrets, and in the development of new products and technologies.
Mr. Metzger brings to Mersana nearly 20 years of experience within the life sciences and pharmaceuticals industries. At Forest Laboratories, he led the mergers and acquisitions function, where he completed deals with Cerexa and Novexel, together forming the cornerstone of Forest's hospital antibiotic franchise, and most recently led the successful acquisition of Clinical Data, Inc. He also led the US co-development and co-promotion deal with Ironwood Pharmaceuticals for Linaclotide. Prior to Forest, Mr. Metzger was Vice President of Corporate Development at Onconova Therapeutics, where he was responsible for the company's business development and financial initiatives. He also served as Managing Director at MESA Partners, a venture capital firm focused on healthcare and IT companies. He serves as a member of the Board of Directors and Chairman of the Finance Committee of Response Genetics, Inc., (NASDAQ: RGDX) a company focused on the development and commercialization of molecular diagnostic tests for cancer. Mr. Metzger earned his B.A. from George Washington University and an M.B.A. in Finance from New York University's Stern School of Business.
Dr. Vincent Miles is a Venture Partner at Abingworth with over 30 years’ experience in the biotechnology industry. Before joining Abingworth in 2007 he was Senior VP of Business Development at Alnylam Pharmaceuticals, an Abingworth portfolio company, where he led the negotiation of important strategic alliances with Novartis, Merck, Medtronic and Biogen Idec. Previously, Vin spent six years at Millennium Pharmaceuticals where he held VP positions in business development, strategic planning and corporate communications, played a key role in the formation of strategic alliances with Monsanto, Bayer and Aventis, and negotiated complex technology collaborations with companies such as Incyte, Lexicon Genetics and Ingenuity Systems. Before joining Millennium he was Director of the technology transfer office at the Dana-Farber Cancer Institute, having previously led R&D and business development at RiboGene, a drug-discovery start-up. The first half of his career was spent in the life sciences “tools” business, initially with Amersham International and then at Pharmacia Biotech, where he held VP positions in R&D and marketing. Vin is on the boards of Hydra Biosciences and PrimeraDx. He holds a BSc in biochemistry and a PhD in molecular biology from University College London.
Jay brings over 20 years of experience in the biopharmaceutical industry. His expertise encompasses leadership roles in entrepreneurial ventures, as well as P&L, commercial/marketing and business development in large pharma and small biopharma organizations. He brings therapeutic area expertise in a wide range of indications, including hematology/oncology and others. As founding CEO, Jay secured a license from Fujisawa (now Astellas) for Gloucester Pharmaceuticals' lead compound, Istodax™ (romidepsin), a novel HDAC inhibitor. He was instrumental in raising over $30 million in initial venture capital financing from blue chip venture capitalists. Istodax was recently approved by the FDA for use in hematologic cancers, which, in turn, led to Gloucester's acquisition by Celgene for $640 million. During his tenure as President and CBO, Jay played a key role in the sale/merger of Variagenics to Hyseq (subsequently Nuvelo and Arca Biopharma) resulting in a 6x return for shareholders. Jay has also served in executive positions at Zelos Therapeutics, Serono (now EMD Serono) and Schering-Plough (now Merck). Jay holds an MBA in Health Care Management and Marketing from The Wharton School and a BA in Economics from Vanderbilt University.
Craig Muir joined Third Rock Ventures in 2007 and leads the identification and integration of drug discovery and development technology platforms for all of our portfolio companies, as well as contributing to scientific diligence for investment opportunities. He also assumes active leadership roles in our portfolio companies, functioning as interim CTO/CIO through the first 12-18 months post launch. In 2010, Craig moved to Third Rock Ventures’ new San Francisco office to oversee the management of the firm’s West Coast-based portfolio companies.
Craig has more than 25 years of technology development, implementation and application experience across the biotechnology and pharmaceuticals industries. Prior to joining Third Rock Ventures, Craig was Senior Vice President, Technical Operations for Codon Devices, and also spent 12 years at Millennium Pharmaceuticals as Vice President of Platform Technology. Earlier in his career, Craig served in a number of executive technology development and scientific roles at Genentech, Tularik and the University of Vermont.
Craig holds a BS in Animal Physiology from University of California – Davis and has co-authored six peer-reviewed scientific papers and is co-inventor on several issued patents. He has directed the development of or collaborated on several technologies that currently serve as the fundamental value driver for a number of biotechnology companies, including Millennium Pharmaceuticals, Portola, xCellerex, Transform and many others.
Dr. Yat Sun Or joined Enanta in November 1999, bringing a distinguished 16-year career in drug discovery and development in the pharmaceutical industry. He held key leadership positions at Abbott Laboratories for 14 years from 1985 to 1999, where he received 2 Chairman’s Awards for his outstanding research, which led to the discovery and development of numerous immunosuppressant and antibacterial drugs. Prior to Abbott, Dr. Or was a member of the cardiovascular drug discovery team at Schering-Plough. He earned his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University. Dr. Or holds over 100 US patents and has published over 60 scientific papers.
Dr. Patterson is an Executive Director in the Medical Sciences function at Amgen leading the In Vitro Diagnostic Group which is responsible for the identification, implementation and management of diagnostic partnering strategies for all Amgen therapeutics (e.g., the development of KRAS as a predictive biomarker and companion diagnostic for Vectibix® therapy). The IVD Group builds upon Amgen's successful biomarker program which Dr. Patterson led as head of Molecular Sciences for its first 8 years. He has published extensively in the field of proteomics and biomarkers, holds editorial board positions and is a frequent guest lecturer. He was previously Vice President of Proteomics at the Celera Genomics Group and the Chief Scientific Officer of Farmal Biomedicines, LLC. While at Celera, he established the company's initial foray into identification of cell surface targets for oncology, a number of which have been licensed. Dr. Patterson was at Amgen from 1993–2000 ultimately leading the Department of Biochemistry and Genetics. His academic career, which encompassed work on analytical protein chemistry applications and apoptosis, began at The University of Queensland where he received his Ph.D. and B.Sc. while holding research positions of increasing responsibility over a period of 11 years, culminating in that of Senior Research Officer. In 1991 he joined the faculty of Cold Spring Harbor Laboratory, New York.
Deanna Petersen joined Shire in 2009 as Vice President of Business Development for Shire Human Genetic Therapies (HGT). Deanna is a broadly skilled senior executive with 15 years of leadership experience in strategic planning and global business development. Deanna is a member of Shire HGT's senior leadership team and is responsible for identifying, evaluating and negotiating business opportunities. Prior to joining Shire, Deanna was a Vice President at Anitgenics' Inc. and Coley Pharmaceutical Group. Deanna is on the Board of Directors for American DG Energy and is Co-Chair of the Business Development Committee for the Massachusetts Biotechnology Association. Deanna holds a Bachelor of Science in Biology from Iowa State University and a Master of Business Administration from The University of Iowa.
Dr. Reddington recently served as President and CEO of Sirtex Medical, Inc., the US division of an Australian publicly traded company Sirtex Medical Group Ltd. (ASX: SIR), where he reorganized and revitalized the US division which accounts for approximately 80% of the corporation’s Aus$66 million in revenue. During John’s last year with Sirtex the divisional sales increased by 29% while expenses were trimmed by 6%, which contributed significantly to the 1,406% increase in net profit (after taxes) that the Company enjoyed.
Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based therapeutics to treat cardiovascular disease. During his tenure John helped secure $30 million in new equity financing, as well as negotiated licensing and supply agreements up to $500 million. In addition, he was responsible for selling off all non-critical assets to facilitate a reverse merger, and spun out the manufacturing division as an independent business unit.
Previously, John founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52-billion global aquaculture market. Earlier in his career, John directed the build-out and operation of an office and cancer cell therapy laboratory for Greenwich Biotherapeutics Inc. a joint venture between Biotherapeutics Inc., Yale University and Greenwich Hospital. Dr Reddington received his B.A. from Rice University, his M.A. from the University of Texas, Arlington and his DVM and PhD from Washington State University.
David Resnick is the co-leader of the Patents practice group at Nixon Peabody. David focuses his practice in the life sciences, including patent procurement, strategic patent management, transactional matters and associated client counseling. He has extensive experience in prosecuting applications for major U.S. research institutions and domestic and international corporations. The subject matter includes proteomics, tissue engineering, drug delivery systems, stem cells, angiogenesis modulation, cancer vaccines, treatment of cancer, immune modulation, medical devices, and diagnostics. David has developed a particular focus on the areas of pharmacogenomics, proteomics and disease biomarkers and their application in the evolving field of personalized medicine.
David has represented major U.S. research institutions, U.S. companies and foreign corporations in interferences before the U.S. Patent and Trademark Office that have involved complex technical areas. He has also assisted clients by evaluating their intellectual property portfolios, as well as the intellectual property held by competitors or potential acquisition targets or partners. In connection with these activities, he has been involved with due diligence and freedom-to-operate analyses and has prepared infringement and validity opinions.
David is a regular contributor to the business and technology website www.xconomy.com.
Dennis Selkoe is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital. A graduate of Columbia University and the University of Virginia School of Medicine, he trained at NINDS, the Harvard/Longwood Neurology Program and the Department of Neuroscience, HMS. Selkoe isolated the neurofibrillary tangles of Alzheimer’s disease (AD) and discovered their unusual insolubility and antigenic relationship to tau. He subsequently conducted extensive research on amyloid ß-protein (Aß) and its precursor (APP) and helped formulate a theory of AD causation, the “amyloid hypothesis”. In 1992, Selkoe and colleagues discovered that Aß is produced by cells throughout life, enabling the dynamic study of Aß generation and screens for Aß inhibitors. They showed that mutations in APP cause AD by increasing Aß production. Selkoe and Michael Wolfe identified presenilin as g-secretase, an unprecedented intramembrane aspartyl protease that processes APP, Notch and many other proteins. Selkoe’s lab showed that small, soluble oligomers of Aß confer synaptotoxicity and memory loss. His work has helped provide the underpinnings of numerous disease-modifying AD clinical trials. He was the principal founding scientist of Athena Neurosciences, now part of Elan Pharmaceuticals. He has received many honors, including the A.H. Heineken Prize for Medicine, the Potamkin Prize, the Metropolitan Life Foundation Award, and the Pioneer Award and Lifetime Achievement Award of the Alzheimer’s Association. He is a Fellow of the American Academy of Neurology, Association of American Physicians and AAAS and member of the Institute of Medicine of the National Academies.
Thomas Scholl, PhD is Vice President for Research & Development at Integrated Genetics/LabCorp. He leads a team responsible for the identification, development & validation of new diagnostic products for LabCorp’s esoteric testing franchises. This includes active projects at LabCorp to bring next-generation sequencing-based products through clinical validation. He is responsible for intellectual property strategy, the translational of advanced technology and scientific discovery into clinical products, and scientific aspects of partnering and licensing relationships. Tom has held this role at LabCorp for the past 1.5 years following the acquisition of Genzyme Genetics where he led R&D for more than 5 years. Before joining Genzyme, Tom led R&D for Myriad Genetic Laboratories for 10 years. He completed his academic training as an American Cancer Society Fellow at Harvard University, following his doctoral work at Penn State University.
John Z. Sullivan-Bólyai, M.D., M.P.H has served as vice president of clinical research at Idenix since July 2007. Prior to joining Idenix, Dr. Sullivan-Bólyai, most recently held leadership positions with Anadys Pharmaceuticals and Valeant Pharmaceuticals where he was responsible for the planning and implementation clinical research activities in Hepatitis C and Hepatitis B. His broad clinical development experience includes HIV, endocrinology, hepatology and coagulation. Dr. Sullivan-Bólyai holds an A.B. degree from Dartmouth College. He received his M.D. and M.P.H. degrees from the University of Washington, Seattle, WA. He completed his infectious diseases fellowship training at Children's Orthopedic Hospital and Medical Center, Seattle, WA.
Barbara joined Satori in 2010. Prior to joining Satori, Barbara was in Pfizer Global Research and Development, where, as a Senior Director, she was responsible for the Alzheimer’s Disease Target Identification and Validation Unit. She was also a member of the Alzheimer’s Disease Area Strategy Team, a company-wide team responsible for developing a long-term vision for the company in this disease area. Barbara had been on the faculties of Harvard Medical School and Brown Medical School prior to joining Pfizer, working to understand the basic mechanisms of neurodegeneration and regeneration. She earned her Ph.D. in Biology from the University of Delaware and completed postdoctoral work at Harvard Medical School.
Dr. Vaishnaw comes to Alnylam from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Member of the Royal College of Physicians, U.K., and received an Executive M.B.A. from Harvard Business School. In addition, Dr. Vaishnaw has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.
Charles Wilson, Ph.D., Vice President & Global Head of Strategic Alliances, Novartis Institutes for BioMedical Research (NIBR)
Charles 'Chuck' Wilson, PhD serves as Vice President and Global Head of Strategic Alliances, leading the group responsible for externally oriented research at the Novartis Institutes for BioMedical Research (NIBR), the business unit of Novartis responsible for drug discovery and early clinical development. Partnering efforts include broad academic relationships to improve the understanding of basic disease processes, biotech collaborations focused on new drug discovery technologies, and in-licensing of compounds that have yet to reach clinical proof-of-concept. Prior to joining Novartis, Chuck founded and led Archemix, a biotech company focused on the development of aptamers as therapeutics. Responsible initially as its Chief Technology Officer for developing the company's technology platform and managing its drug discovery efforts, he moved into a business role focused on establishing partnerships with large pharma and biotech companies. Before moving into industry, Chuck was an Associate Professor of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz. There he determined the first x-ray crystal structures of RNA aptamers bound to their targets. Formally trained in structural biology and molecular biology, Chuck received his PhD from the University of California, San Francisco and his post-doctoral training in the Department of Molecular Biology at Massachusetts General Hospital.
Dr. Woolf has twenty years of experience developing and commercializing innovative biomedical technologies, including fifteen years of biotechnology management experience. Dr. Woolf co-founded RXi Pharmaceuticals in 2006 and brought the company public as CEO in 2008. Previously, he founded and served as CEO of Sequitur, an RNAi company acquired by Invitrogen (Nasdaq: IVGN) in 2003. Prior to that, he helped to develop and partner the core therapeutic technology at RPI (now Sirna/Merck) and Ontogeny (now Curis). Dr. Woolf has served as a scientific and business advisor to a number of biotechnology companies including Praecis, Invitrogen, Advirna, Adarza and TriLink Biotechnologies. He holds a Masters and Ph.D. in Cellular and Development Biology from Harvard University and has authored 40 patent applications and scientific publications.